Spots Global Cancer Trial Database for egfr exon 20 insertion
Every month we try and update this database with for egfr exon 20 insertion cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients | NCT05751187 | Non-squamous NS... | Pembrolizumab Bevacizumab Pemetrexed Cisplatin Carboplatin Folic acid 350-... Vitamin B12 100... Dexamethasone 4... | 18 Years - 75 Years | Shanghai Chest Hospital | |
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients | NCT05751187 | Non-squamous NS... | Pembrolizumab Bevacizumab Pemetrexed Cisplatin Carboplatin Folic acid 350-... Vitamin B12 100... Dexamethasone 4... | 18 Years - 75 Years | Shanghai Chest Hospital | |
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | NCT05940116 | Non-Small Cell ... Solid Tumor | HS-20117 | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients | NCT05751187 | Non-squamous NS... | Pembrolizumab Bevacizumab Pemetrexed Cisplatin Carboplatin Folic acid 350-... Vitamin B12 100... Dexamethasone 4... | 18 Years - 75 Years | Shanghai Chest Hospital | |
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | NCT05940116 | Non-Small Cell ... Solid Tumor | HS-20117 | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca |